Company: HURA
Filing Date: 2025-02-07
Form Type: S-4
Source: 0001193125-25-022803
Chunk: 578

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-02-07
Form: S-4
Chunk 578
---
 from Nasdaq. Financial Operations Overview Revenues To date, Kineta has not generated any revenue from product sales and do not expect to generate any revenue from product sales in the near future. Kineta’s revenues have been primarily derived from Kineta’s collaboration, research and license agreements as well as grants awarded by government agencies. Kineta has completed research and development services under the grant agreements and do not expect to recognize any revenue during 2024. Operating Expenses Research and Development Expenses Research and development expenses represent costs incurred in connection with the discovery, research, preclinical and clinical development, and manufacture of Kineta’s product candidates. Kineta recognizes all research and development costs as they are incurred. Research and development expenses consist primarily of the following:

| • |     | salaries, bonuses, benefits, stock-based compensation, research and consulting arrangements and other related costs for individuals involved in research and development activities; |

| • |     | external research and development expenses incurred under agreements with contract research organizations, investigative sites and other scientific development services; |

| • |     | costs incurred under agreements with contracted research and manufacturing organizations for developing and manufacturing materials for preclinical studies, clinical trials and laboratory supplies; |

| • |     | licensing agreements and associated costs; |

373

| • |     | costs related to compliance with regulatory requirements; |

| • |     | facilities and other allocated expenses for rent and insurance; and |

| • |     | other expenses incurred to advance research and development activities including manufacturing costs associated with production, scale up, testing and optimization of methods associated with the production of materials. |

Subject to receiving adequate funding, Kineta expects Kineta’s research and development expenses to increase in the future as Kineta advances Kineta’s product candidates into and through clinical trials and pursue regulatory approvals, which will require a significant investment in costs of clinical trials, regulatory support and contract manufacturing. In addition, Kineta continues to evaluate opportunities to acquire or in-licenseother product candidates and technologies, which may result in higher research and development expenses due to license fee and/or milestone payments, as well as added clinical development costs. As Kineta is working on multiple research and development programs at any one time, Kineta tracks Kineta’s external expenses by the stage of program, clinical or preclinical. However, Kineta’s internal expenses, including unallocated costs, personnel costs and infrastructure costs, are not directly related to any one program and are deployed across multiple programs. As such, Kineta does not track internal expenses on a specific program basis.